[{"id":"0548374d-6bbb-45ae-b3fa-1857817c4f14","acronym":"MARGOT","url":"https://clinicaltrials.gov/study/NCT04425018","created_at":"2021-01-18T21:19:01.180Z","updated_at":"2025-02-25T12:27:36.881Z","phase":"Phase 2","brief_title":"MARGetuximab Or Trastuzumab (MARGOT)","source_id_and_acronym":"NCT04425018 - MARGOT","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab) • Herzuma (trastuzumab-pkrb) • Margenza (margetuximab-cmkb) • Ogivri (trastuzumab-dkst)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 174","initiation":"Initiation: 07/13/2020","start_date":" 07/13/2020","primary_txt":" Primary completion: 09/05/2024","primary_completion_date":" 09/05/2024","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-10-02"},{"id":"3fa8b4e4-5808-4ba8-b524-7db4cfb6614d","acronym":"MAHOGANY","url":"https://clinicaltrials.gov/study/NCT04082364","created_at":"2021-01-17T17:54:33.576Z","updated_at":"2024-07-02T16:35:03.564Z","phase":"Phase 2/3","brief_title":"Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer","source_id_and_acronym":"NCT04082364 - MAHOGANY","lead_sponsor":"MacroGenics","biomarkers":" PD-L1 • MSI","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive","tags":["PD-L1 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • 5-fluorouracil • capecitabine • oxaliplatin • Margenza (margetuximab-cmkb) • Zynyz (retifanlimab-dlwr) • tebotelimab (MGD013)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 09/30/2019","start_date":" 09/30/2019","primary_txt":" Primary completion: 01/15/2024","primary_completion_date":" 01/15/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-05-15"},{"id":"db068b7e-0c84-41a8-8c88-e6838f8d4682","acronym":"","url":"https://clinicaltrials.gov/study/NCT03219268","created_at":"2021-01-17T17:21:23.536Z","updated_at":"2024-07-02T16:35:25.591Z","phase":"Phase 1","brief_title":"A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms","source_id_and_acronym":"NCT03219268","lead_sponsor":"MacroGenics","biomarkers":" PD-L1 • PD-1 • LAG3","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • LAG3 expression • MHC-II expression","tags":["PD-L1 • PD-1 • LAG3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • LAG3 expression • MHC-II expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Margenza (margetuximab-cmkb) • tebotelimab (MGD013)"],"overall_status":"Completed","enrollment":" Enrollment 277","initiation":"Initiation: 08/18/2017","start_date":" 08/18/2017","primary_txt":" Primary completion: 02/08/2023","primary_completion_date":" 02/08/2023","study_txt":" Completion: 02/08/2023","study_completion_date":" 02/08/2023","last_update_posted":"2023-12-21"},{"id":"896f76a1-c728-4372-8d4d-cbf47ca08f56","acronym":"SOPHIA","url":"https://clinicaltrials.gov/study/NCT02492711","created_at":"2021-01-17T17:27:28.437Z","updated_at":"2024-07-02T16:35:59.992Z","phase":"Phase 3","brief_title":"Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer","source_id_and_acronym":"NCT02492711 - SOPHIA","lead_sponsor":"MacroGenics","biomarkers":" ER • PGR","pipe":"","alterations":" ","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Margenza (margetuximab-cmkb)"],"overall_status":"Completed","enrollment":" Enrollment 624","initiation":"Initiation: 08/24/2015","start_date":" 08/24/2015","primary_txt":" Primary completion: 08/11/2021","primary_completion_date":" 08/11/2021","study_txt":" Completion: 06/14/2022","study_completion_date":" 06/14/2022","last_update_posted":"2022-11-23"},{"id":"a87ef28d-a7d2-443e-8a4d-8344602ace86","acronym":"","url":"https://clinicaltrials.gov/study/NCT01148849","created_at":"2021-01-18T04:34:22.177Z","updated_at":"2024-07-02T16:36:02.202Z","phase":"Phase 1","brief_title":"Safety Study of MGAH22 in HER2-positive Carcinomas","source_id_and_acronym":"NCT01148849","lead_sponsor":"MacroGenics","biomarkers":" HER-2 • FCGR3A","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2 • FCGR3A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Margenza (margetuximab-cmkb)"],"overall_status":"Completed","enrollment":" Enrollment 66","initiation":"Initiation: 07/01/2010","start_date":" 07/01/2010","primary_txt":" Primary completion: 06/14/2022","primary_completion_date":" 06/14/2022","study_txt":" Completion: 06/14/2022","study_completion_date":" 06/14/2022","last_update_posted":"2022-10-19"},{"id":"af1cde65-7b68-4825-ade0-7820404d0e79","acronym":"","url":"https://clinicaltrials.gov/study/NCT02689284","created_at":"2021-01-17T17:32:40.343Z","updated_at":"2025-02-25T16:04:21.613Z","phase":"Phase 1b/2","brief_title":"Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer","source_id_and_acronym":"NCT02689284","lead_sponsor":"MacroGenics","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Margenza (margetuximab-cmkb)"],"overall_status":"Completed","enrollment":" Enrollment 95","initiation":"Initiation: 01/01/2016","start_date":" 01/01/2016","primary_txt":" Primary completion: 01/01/2021","primary_completion_date":" 01/01/2021","study_txt":" Completion: 01/01/2021","study_completion_date":" 01/01/2021","last_update_posted":"2022-08-04"},{"id":"0a0fb4db-6a19-425f-83f2-8f29486f4005","acronym":"MARGARET","url":"https://clinicaltrials.gov/study/NCT05227131","created_at":"2022-02-12T17:47:42.396Z","updated_at":"2024-07-02T16:36:07.534Z","phase":"Phase 2","brief_title":"Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer","source_id_and_acronym":"NCT05227131 - MARGARET","lead_sponsor":"MedSIR","biomarkers":" ER • PGR • FCGR3A","pipe":" | ","alterations":" HER-2 positive","tags":["ER • PGR • FCGR3A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • Tukysa (tucatinib) • Margenza (margetuximab-cmkb)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/15/2022","start_date":" 05/15/2022","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2022-07-11"},{"id":"d8ec50de-3014-422a-ae8c-f3c342df9a75","acronym":"","url":"https://clinicaltrials.gov/study/NCT01828021","created_at":"2021-01-18T08:07:29.768Z","updated_at":"2024-07-02T16:36:17.314Z","phase":"Phase 2","brief_title":"Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer","source_id_and_acronym":"NCT01828021","lead_sponsor":"MacroGenics","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 amplification • HER-2 expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Margenza (margetuximab-cmkb)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 03/01/2013","start_date":" 03/01/2013","primary_txt":" Primary completion: 12/07/2016","primary_completion_date":" 12/07/2016","study_txt":" Completion: 04/14/2017","study_completion_date":" 04/14/2017","last_update_posted":"2022-02-10"},{"id":"b07dc0e4-b4c7-455e-a076-4f4f7c691bc6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01195935","created_at":"2021-01-18T04:47:15.613Z","updated_at":"2024-07-02T16:37:20.936Z","phase":"Phase 1","brief_title":"A Phase I Study of MGAH22 in Patients With Refractory HER2 Positive Cancers","source_id_and_acronym":"NCT01195935","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Margenza (margetuximab-cmkb)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 08/01/2010","start_date":" 08/01/2010","primary_txt":"","primary_completion_date":"","study_txt":" Completion: 08/01/2014","study_completion_date":" 08/01/2014","last_update_posted":"2017-06-19"}]